{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-25-000136","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.358074+00:00","generated_at":"2026-05-17T21:10:54.574486+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10","bullets":["Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.","FY 2025 revenue guidance reaffirmed at $61B-$64B; adjusted EPS guidance raised by $0.10 to $2.90-$3.10.","Vyndaqel family revenue up 21% operationally; Comirnaty +95%; Paxlovid +71%; Padcev +38%; Eliquis +6%.","Completed $1.25B upfront in-licensing of 3SBio's SSGJ-707; one-time ~$0.20 EPS impact in Q3.","On track for $7.2B net cost savings by end of 2027; capital allocation includes $4.9B dividends in H1."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-25-000136","json":"https://secwatch.observer/filing/0000078003-25-000136.json","markdown":"https://secwatch.observer/filing/0000078003-25-000136.md","text":"https://secwatch.observer/filing/0000078003-25-000136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/0000078003-25-000136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:10:54.574486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}